Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)
Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of Nilotinib for patients with advanced GIST that cannot be
surgically removed. Patients are candidates for the study if their tumors have progressed on
imatinib and sunitinib or if they were intolerant to these drugs. Patients may have received
other investigational therapies as well. We are testing the benefit of nilotinib in advanced
GIST looking at the length of time disease is controlled as well as the response of the
disease to the drug.